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Patterns of somatic structural variation in 
human cancer genomes
Yilong Li1,2,14, Nicola D. Roberts1,14, Jeremiah A. Wala3,4,5,14, Ofer Shapira3,4,5,14,  
Steven E. Schumacher3,4,5, Kiran Kumar3,4,5, Ekta Khurana6, Sebastian Waszak7, Jan O. Korbel7, 
James E. Haber8, Marcin Imielinski9, PCAWG Structural Variation Working Group10,  
Joachim Weischenfeldt11*, Rameen Beroukhim3,4,5*, Peter J. Campbell1,12* &  
PCAWG Consortium13
A key mutational process in cancer is structural variation, in which rearrangements 
delete, amplify or reorder genomic segments that range in size from kilobases to 
whole chromosomes1–7. Here we develop methods to group, classify and describe 
somatic structural variants, using data from the Pan-Cancer Analysis of Whole 
Genomes (PCAWG) Consortium of the International Cancer Genome Consortium 
(ICGC) and The Cancer Genome Atlas (TCGA), which aggregated whole-genome 
sequencing data from 2,658 cancers across 38 tumour types8. Sixteen signatures of 
structural variation emerged. Deletions have a multimodal size distribution, assort 
unevenly across tumour types and patients, are enriched in late-replicating regions 
and correlate with inversions. Tandem duplications also have a multimodal size 
distribution, but are enriched in early-replicating regions—as are unbalanced 
translocations. Replication-based mechanisms of rearrangement generate varied 
chromosomal structures with low-level copy-number gains and frequent inverted 
rearrangements. One prominent structure consists of 2–7 templates copied from 
distinct regions of the genome strung together within one locus. Such cycles of 
templated insertions correlate with tandem duplications, and—in liver cancer—
frequently activate the telomerase gene TERT. A wide variety of rearrangement 
processes are active in cancer, which generate complex configurations of the genome 
upon which selection can act.
Mutations that arise in somatic cells are the driving force of cancer 
development. Structural variation—in which genomic rearrangement 
acts to amplify, delete or reorder chromosomal material at scales that 
range from single genes to entire chromosomes—is an especially impor-
tant class of somatic mutation. Previous analyses of both cancer and 
germline genomes have enabled the description of several distinctive 
patterns of structural variants1–7, and hypotheses about the underlying 
basis of several of these patterns have been proposed on the basis of 
their clustering, orientation and associated copy-number changes. 
Hypothesis-driven in vitro studies are now beginning to reveal some 
of the mechanistic processes that generate these structures9–13, and 
generate further predictions that can be assessed in the genomic data. 
However, the landscape of structural variation in human cancer remains 
incompletely mapped and there are many complex structures that 
elude formal description.
The PCAWG Consortium aggregated whole-genome sequencing 
data from 2,658 cancers across 38 tumour types, generated by the ICGC 
and TCGA projects. These sequencing data were aligned to the human 
genome (reference build hs37d5) and analysed with standardized, high-
accuracy pipelines to call somatic and germline variants of all classes8. 
Here, we analyse the patterns and signatures of structural variants 
across the PCAWG data. We propose a working classification scheme 
that encompasses known and newly identified classes of structural vari-
ants. We develop methods for annotating the observed structural vari-
ants in a given cancer genome, identifying a class of replication-based 
rearrangement processes that generate clusters of several structural 
variants. We explore the size, activity and genome-wide distribution of 
classifiable structural variant types across the cohort, using signature 
analysis to define how they correlate within patients. Other papers 
produced by PCAWG address complementary aspects of structural 
variants, including inference of positive selection acting on recurrently 
rearranged regions of the genome14, how structural variants affect the 
transcriptome15 and chromosome topology16, patterns of somatic retro-
transposition17 and distribution of chromothripsis across cancer types18.
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Classification of structural variants
A ‘structural variant’ manifests as a ‘junction’ between two ‘breakpoints’ 
in the genome (terms in inverted commas here and below refer to those 
defined in the glossary in Extended Data Table 1). Generally, there will 
be a change in copy number across a given breakpoint if only one side 
of the break is rescued by a structural variant; if both sides of a double-
stranded DNA break are rescued, a ‘reciprocal’ or ‘balanced’ struc-
tural variant will result, without substantial copy-number change. We 
sometimes observe ‘clusters of structural variants’ in which several 
breakpoints occur close together, in time or in genomic space—usually 
both. Such spatial and/or temporal proximity generally, but not always, 
implies that the structural variants within a cluster are mechanistically 
linked. Clusters can be ‘phased’ (in which case all structural variants in 
the cluster resolve to a single derivative chromosome) or ‘unphased’, 
in which case the structural variants are carried on different derivative 
chromosomes. An example of the latter is a reciprocal translocation 
that results in two derivative chromosomes, each with a single inter-
chromosomal breakpoint junction (Fig. 1).
We recognize distinct ‘classes of structural variant’ from the orienta-
tion of the two segments at the junction and associated copy-number 
changes (Fig. 1, Supplementary Fig. 1). Some classes of structural vari-
ant (such as isochromosomes and rearrangements between extended, 
highly homologous sequences) are difficult to detect with short-read 
sequencing data; these classes are not considered further here. We 
propose categorizing classes of structural variant across two facets: the 
number of breakpoints involved (simple or complex) and by whether 
the patterns are likely to arise from ‘cut-and-paste’ or ‘copy-and-paste’ 
rearrangement processes. A cut-and-paste process generates a clus-
ter of structural variants consistent with reshuffling or loss of extant 
genomic segments, and a copy-and-paste process is one in which cop-
ies of genomic ‘templates’ are newly replicated or synthesized and 
inserted during the rearrangement process. Deletions, reciprocal 
inversions, unbalanced translocations and reciprocal translocations 
are examples of simple cut-and-paste structural variants, as they can 
be reconstructed from the incorrect religation of chromosomal breaks. 
Tandem duplications are simple copy-and-paste structural variants, as 
they arise through the local insertion of a newly generated extra copy 
of a genomic template.
More-complex cut-and-paste processes that produce structural 
variants also occur in cancer. ‘Breakage–fusion–bridge’ events result 
from cycles of DNA breakage, end-to-end sister chromatid fusions, 
mitotic bridges and further DNA breakage. These events manifest as 
one or a few proximate, inverted breakpoint junctions with associated 
copy-number change, which we call ‘fold-back inversions’1,2,19 (Fig. 1). 
‘Chromoplexy’5,20—which is particularly frequent in prostate cancers—
results from several simultaneous double-stranded DNA breaks in 
several chromosomes that are rejoined incorrectly, leading to balanced 
chains of rearrangements. ‘Chromothripsis’3, in which chromosome 
shattering and rearrangement occur in a single catastrophic event9,21, 
leads to a pattern of oscillating copy-number changes and localized 
clustering of tens to hundreds of breakpoints22.
In the germline, more-complex copy-and-paste classes of structural 
variant have previously been described, which involve small duplica-
tions and triplications and are thought to arise from the stalling of the 
replication fork leading to template switching4,23,24. Here we describe 
a wide range of complex copy-and-paste types of somatic structural 
variant that occur in human cancers, and that are typically character-
ized by copy-number gains and frequent inverted rearrangements.
Annotation of structural-variant classes
We analysed 2,559 whole cancer genomes across 38 tumour types 
(alongside matched germline DNA) that passed the most stringent 
PCAWG quality-control criteria: 1 or more somatic structural variants 
were detected in 2,429 tumours8. As described in an accompanying 
Article8, structural variants were identified using aberrantly map-
ping and/or split reads in paired-end sequencing data25. We used four 
somatic structural-variant callers20,25–27, and the final structural-variant 
dataset comprised events that were returned by ≥2 callers, merged 
by a graph-based consensus method8. We consider only somatically 
acquired structural variants in this analysis, and exclude somatic 
retrotransposition events. Validation of structural-variant calls was 
undertaken using both manual inspection and pull-down with rese-
quencing of breakpoints. With these approaches, we estimate the 
sensitivity of the consensus structural-variant call set to be 90% for 
true calls generated by any 1 of the 4 callers; specificity was estimated 
as 97.5%8. A mean of 3.22 algorithms of the 4 that we used called each 
structural variant in the consensus set genome-wide, and this dif-
fered little across repetitive elements: the mean for short interspersed 
nuclear elements was 3.22, and the mean for long interspersed nuclear 
elements was 3.21.
Because the structural variants from a given cancer are often highly 
clustered, we grouped rearrangements into clusters on the basis of the 
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Fig. 1 | Classification of structural variants in cancer genomes. Schematics of 
major structural-variant (SV) classes, grouped according to whether they are 
simple or complex and arise through cut-and-paste or copy-and-paste 
processes. Each schematic comprises three parts. The top segment shows 
dotted arcs for each rearrangement junction that joins two chromosomal 
segments together. The middle segment shows the copy number of genomic 
segments that are involved. The bottom segment shows the configuration of 
the final derivative chromosome that results from the structural variant; the 
colour of the segments corresponds to the colour of that segment in the copy-
number schematic. + indicates the different derivative chromosomes created 
for some of the classes: that is, the structural variants are not phased to a single 
derivative.
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proximity of breakpoints, the overall number of events in that genome 
and the size distribution of these events (Supplementary Methods). 
Essentially, a particular cluster contains structural variants that are 
significantly closer together than expected by chance, given the overall 
number and orientation of structural variants in that patient. Alongside 
the clustering, we computed an in silico library of all possible genomic 
configurations that result from sequential simple structural variants 
(deletions, tandem duplications, inversions, translocations, and chro-
mosome duplications or losses), to a depth of five rearrangements. 
We could then compare the genomic configuration of each observed 
cluster of structural variants against the library to determine how it 
might have arisen.
This methodology has the advantage that breakpoint junctions are 
classified according to the wider genomic context in which they occur. 
This means that, for example, true deletions will be identifiably dif-
ferent from breakpoint junctions that happen to have a deletion-type 
orientation but arise within (for instance) a chromothripsis event of 
markedly different mechanism and properties. Over half the break-
point junctions that we observed arise within clusters of several or 
many structural variants (Fig. 2a): removing these junctions from the 
catalogues of true deletions, tandem duplications and inversions ena-
bles a more-precise description of the properties of simple structural 
variants.
Among the classes of simple structural variants, deletion was the 
most common, followed by tandem duplication and then unbalanced 
translocation. Reciprocal translocations and reciprocal inversions 
were uncommon events (Fig. 2a). There was considerable variability 
in the overall numbers and distribution of classes of structural variant 
across tumour types and across patients within a given tumour type 
(Extended Data Fig. 1). For example, oesophageal adenocarcinomas 
were characterized by many deletions and a large number of complex 
clustered rearrangements (Fig. 2b), and ovarian cancers often carried 
high numbers of tandem duplications and/or deletions with moderate 
numbers of unbalanced translocations (Fig. 2c).
Cycles of templated insertions
We next examined clusters that contain 2–10 structural variants. One 
newly identified configuration consisted of several segments of copy-
number gains, typically on different reference chromosomes, linked 
together through structural variants (Fig. 3, Extended Data Fig. 2). 
A sequential path through consecutive segments can be formed by 
following the breakpoint junctions, which suggests that each clus-
ter represents a string of duplicated templates inserted into a single 
derivative chromosome, probably acquired concurrently. Although it 
is theoretically possible that the structural variants in such clusters are 
not phased on the same derivative chromosome or do not occur con-
currently, we think this is unlikely for several reasons. First, we found 
examples of RNA transcripts that spliced together exons separated 
by two junctions in the structural-variant cluster (Supplementary 
Fig. 2), which suggests that they are phased on the same derivative 
chromosome. Second, long-read sequencing data (reported in an 
accompanying Article8) supported the phasing of structural variants 
that link templated insertions. Third, we found that the clonal frac-
tion of tumour cells tended to be more similar for structural variants 
within these clusters than for randomly chosen structural variants 
in each patient (Supplementary Fig. 3), which suggests that they co-
occur in evolutionary time. Fourth, the level of copy-number gain 
for individual segments in the cluster tended to be identical (Fig. 3, 
Extended Data Fig. 2).
We define three basic categories on the basis of whether or not the 
string of inserted segments returns to the original chromosome: we 
term strings of inserted segments that do not return ‘chains’ of tem-
plated insertions and those strings that do return ‘bridges’ (which 
leave a gap on the host chromosome) or ‘cycles’ (which rereplicate 
a segment on the host chromosome). In the PCAWG dataset overall, 
we observed 1,467 cycles and 1,275 bridges of templated insertions 
(Fig. 3a, b, Extended Data Fig. 2). In chains of templated insertions, 
the string of genomic segments does not return to the chromosome 
of departure (Fig. 3c, Extended Data Fig. 2) but it is similarly associ-
ated with copy-number gains at each templated segment. There were 
285 instances of such chains in the dataset, commonly manifesting as 
unbalanced translocations joined through one or more intermediary 
templated insertions.
Most templated insertion events involve only two breakpoint 
junctions, but this can extend to three, four or more linked rear-
rangements (Extended Data Fig. 3a). The longest such event—from 
a cervical squamous cell cancer—had seven templated insertions 
strung together on an eighth host chromosome (Fig.  3c; other 
examples of long templated insertion events are shown in Extended 
Data Fig. 3).
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Fig. 2 | Frequency of structural-variant classes across tumour types. a, Violin 
plots of density of classified structural-variant categories across patients 
within each histology group. Tumour type panels are sorted in descending 
order of the average number of structural-variant breakpoints per sample. 
Within each tumour type, the frequency distribution ( y axis) of different 
structural-variant categories (x axis) across patients is shown as a density: 
regions of highest density have the greatest width of shaded area. In each 
panel, the number of patients is indicated at the top right. AdenoCA, 
adenocarcinoma; BNHL, B-cell non-Hodgkin lymphoma; ChRCC, 
chromophobe renal cell carcinoma; CLL, chronic lymphocytic leukaemia; CNS, 
central nervous system; GBM, glioblastoma; HCC, hepatocellular carcinoma; 
leiomyo, leiomyosarcoma; medullo, medulloblastoma; MPN, 
myeloproliferative neoplasm; eso, oesophageal; oligo, oligodendrocytic; panc, 
pancreatic; piloastro, pilocytic astrocytoma; prost, prostate; RCC, renal cell 
carcinoma; sarc, sarcoma; SCC, squamous cell carcinoma; TCC, transitional cell 
carcinoma; thy, thyroid. b, Per-sample counts of complex (bottom) and 
classified (top) structural-variant breakpoint junctions for oesophageal 
adenocarcinoma. c, Per-sample counts of complex (bottom) and classified 
(top) structural-variant breakpoint junctions for ovarian adenocarcinoma.
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Templated insertions that affect TERT
Structural variants drive tumour development through their effects 
on cancer genes, whether by altering gene copy number, disrupting 
tumour-suppressor genes, creating fusion genes or juxtaposing the 
coding sequence of one gene with the regulatory apparatus of another. 
We found that many liver cancers had cycles of templated insertions 
that affect TERT (Fig. 3d, e, Extended Data Fig. 4). Point mutations in 
the TERT promoter are present in 54% of liver cancers, and a further 
5–10% of liver cancers have structural variants that activate the gene28. 
Of the 30 patients with liver cancer that had structural variants that 
affect TERT, we find that 10 of these variants were templated inser-
tion events (mostly cycles). All of these events duplicated the entire 
TERT gene and linked it to duplications of whole genes, fragments of 
genes or regulatory elements from elsewhere in the genome, and led 
to increased expression of TERT (Extended Data Fig. 4e). Thus, this 
particular rearrangement process is distinctive for the precision with 
which cancer copy-and-pastes normally disparate functional elements 
of its genome together without wholesale instability.
Tumour-suppressor genes were also inactivated by templated inser-
tions (Extended Data Fig. 5). For example, among many straightforward 
deletions, RB1 was hit by cycles of templated insertions, a templated 
insertion with deletion and one instance of the linked, inverted dupli-
cations detailed in ‘Local n-jumps and local–distant clusters’. These 
events typically generated duplications of internal exons in RB1 and/or 
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gene, in two hepatocellular carcinomas. KIAA1024 is also known as MINAR1.
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insertions of exons from other genes, all of which presumably rendered 
a non-functional transcript.
Local n-jumps and local–distant clusters
Many clusters of 2–10 structural variants in the dataset were confined 
to a single genomic region. Of those clusters that comprised two local 
rearrangements, some had straightforward explanations, such as 
nested or adjacent tandem duplications. However, many did not have 
a trivial explanation (Fig. 4a). These included a duplication–inverted-
triplication–duplication structure that has previously been observed in 
germline structural variants24 (349 instances); a structure of two dupli-
cations linked by inverted rearrangements (531 instances); and struc-
tures of copy-number loss plus nearby duplication linked by inverted 
rearrangements (472 instances). All of these patterns had solutions in 
which breakpoints were phased to a single derivative chromosome 
(Fig. 4a), although non-phased solutions are theoretically possible 
(if unlikely). Beyond clusters of two rearrangements (two-jumps), we 
also found examples involving three, four or more rearrangements 
confined to one genomic locale (Fig. 4b). All of these configurations 
of clusters of structural variants can be phased to a single derivative 
chromosome, with tightly grouped breakpoints.
Beyond clusters confined to a single genomic region, we found 
clusters of 2–10  structural variants that combined local jumps 
with rearrangements that reach into one or more distant regions 
of the genome (Fig. 4c). Simple examples of these events include 
unbalanced translocations or large deletions with a locally derived 
fragment inserted at the breakpoint, but there was also an extensive 
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range of more-complex patterns. In some cases, the source of the 
inserted fragment was distal to the major break, and the structural vari-
ant could feasibly result from several concurrent DNA breaks in close 
spatial proximity to the capture of a short DNA fragment during repair 
(cut-and-paste). In other cases, the origin of the inserted fragment 
was proximal to the major break and associated with a gain in copy 
number. This pattern is difficult to explain by a cut-and-paste mecha-
nism, because the copy-number gain implies the inserted segment 
was a duplicate of the original template rather than a separated frag-
ment redistributed from its original locus. Instead, a copy-and-paste 
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mechanism may be the more parsimonious explanation for these 
events.
A comparison of local footprints linked together through distant 
rearrangements revealed a strong connectivity of footprints with the 
same or similar structure, often enriched tenfold or more than expected 
by chance (see ‘Footprint connectivity analysis’ in Supplementary 
Results). The reasons for this are unclear, but it may reflect innate struc-
tural symmetry introduced through the generation or the resolution 
of rearrangements, or through the repeated action of a mechanism 
that imparts consistent structural motifs.
Copy-and-paste patterns of clusters
The diverse patterns of 2–10 clustered structural variants (Figs. 3, 4) 
share important morphological features: (1) genomic configurations 
that can be phased to a single derivative chromosome; (2) low-level 
gains in copy number, especially duplications and triplications; (3) a 
high frequency of inverted rearrangements in addition to noninverted 
rearrangements; (4) occurrence on a chromosome background with 
similar average copy number to the tumour overall; and (5) tight prox-
imity of breakpoints within the local footprint (typically <1 Mb).
Using our in silico library of genomic configurations, we could define 
all possible routes by which sequential structural variants could gener-
ate these structures through the classically defined repertoire of dele-
tion, tandem duplication, inversion and translocation (Supplementary 
Fig. 4). These routes typically would require implausible machinations 
of chromosomes (Supplementary Results). In particular, the high preva-
lence of inverted breakpoint junctions and local copy-number gains is 
difficult to recreate using sequential simple rearrangements. Simple 
inversion events are uncommon in cancers (Fig. 1d) and they tend not to 
generate copy-number gains, except through breakage–fusion–bridge 
cycles: these latter also cause terminal deletions2, which are not seen 
in the events discussed here.
If these events cannot be satisfactorily explained by sequential 
simple rearrangements, another possible explanation is a complex 
cut-and-paste mechanism such as chromothripsis, chromoplexy or 
repeated breakage–fusion–bridge cycles. However, the patterns of 
the 2–10 clustered structural variants do not fit with these processes 
either (Supplementary Results). Although chromothripsis with copy-
number gain has previously been described3,11,19,22, the resulting copy 
number and rearrangement patterns have different properties to those 
we observed. Chromoplexy, in which chromosome breaks lead to a 
balanced interchange at multiple breakpoint junctions5,20, typically gen-
erates unphased solutions. Repeated breakage–fusion–bridge cycles 
tend to cause high-level copy-number gains associated with inverted, 
fold-back rearrangements1,2, unlike the structures reported here.
Instead, we believe that many of these locally complex clusters of 
structural variants with low-level copy-number gains are generated 
in a single event by a copy-and-paste process. That is, the copying of 
genomic templates is an intrinsic aspect of the structural variation pro-
cess in these events, with the extra copies being inserted in the resulting 
derivative chromosome. If the genomic templates all originate locally, 
we would observe local n-jumps (such as in Fig. 3a, b) with a tight cluster-
ing of breakpoints, phased solutions, frequent copy-number gains and 
a mix of inverted and noninverted breakpoint junctions. If the original 
templates for the copied segments derive from across the genome, 
chains, cycles and bridges of templated insertions would arise (Fig. 2).
Genomic properties of structural variants
The size of tandem duplications and deletions followed complex—often 
multimodal—distributions across tumour types (Fig. 5a, Extended 
Data Fig. 6a). However, as previously reported6,29, individual patients 
tend to have a simpler—usually unimodal—distribution of deletions or 
tandem duplications (Extended Data Fig. 6b), which implies that the 
complexity seen in a given tumour type results from combining samples 
with different profiles. The sizes of individual fragments in templated 
insertion events were also distinctly multimodal, with varying peak 
heights across tumour types (Fig. 5b). When correlating template sizes 
within a given event, two patterns emerged: one in which template 
sizes were closely correlated with one another, and one in which a small 
(<1 kb) template was linked with one of any size (Extended Data Fig. 7a, 
b). Likewise, the sizes of segments within a given local two-jump event 
showed moderately strong correlations with one another (Extended 
Data Fig. 7c).
A number of genomic properties (such as replication timing, tran-
scriptional activity and chromatin state) influence the density of point 
mutations30,31 and copy-number alterations32, but how this relates to 
individual classes of structural variant is unclear. From the literature, 
we compiled a library of the genome-wide distribution of 38 features 
including replication timing, GC content, repeat density, gene density 
and distance to G-quadruplex motifs, among others. Replication timing 
had the strongest association with the occurrence of structural vari-
ants; deletions are enriched in late-replicating regions, and tandem 
duplications and unbalanced translocations occur preferentially in 
early-replicating regions (Fig. 5c, Extended Data Fig. 8). For individual 
patients with high numbers of deletions or tandem duplications, we 
observed notable heterogeneity in the distribution of these struc-
tural variants according to replication timing: some had events that 
occurred predominantly in late-replicating regions, others had events 
that occurred exclusively in early-replicating regions, and in others 
events were distributed more evenly (Supplementary Fig. 5). Regions 
of active chromatin and increased gene density correlated positively 
with the rate of rearrangement.
A structural variant requires DNA repair pathways to join two 
sequences together, and several repair mechanisms are available to 
somatic cells. Some require sequence homology between the two ends, 
and others can operate to join non-homologous sequences. As previ-
ously reported2,25,33, we find across the PCAWG data that many structural 
variants do not have sequence homology at the breakpoint junction 
(Fig. 5d) and therefore arise through non-homologous end joining. 
Nonetheless, a sizable fraction of structural variants has more micro-
homology than expected by chance, with an apparently bimodal dis-
tribution of microhomology lengths. One set of structural variants 
has 2–7 bp of microhomology, probably generated by microhomol-
ogy-mediated end joining, and a second set of structural variants has 
10–30 bp of microhomology, probably generated through single-strand 
annealing or other forms of homologous recombination (including 
microhomology-mediated break-induced replication). Repetitive 
sequences in the genome, such as short and long interspersed nuclear 
elements, are the likely substrate of such structural variants, and we 
find enrichment for structural variants joining such elements (Fig. 5e, 
Supplementary Fig. 6).
Signatures of structural variation
The heterogeneous spectrum of point mutations across cancers can 
be reconstructed from the differential action of a relatively limited 
repertoire of mutational processes, each with a characteristic signa-
ture34. The differences across patients in the size distribution of tandem 
duplication and deletion—together with the widely varying frequency 
and patterns of structural variant across tumour types and genome 
topology—suggested that we could similarly learn such correlations 
across individual classes of structural variant.
We divided the set of structural variants of each patient into mutu-
ally exclusive categories. We split the most frequent classes of simple 
structural variant (deletions and tandem duplications) into 11 catego-
ries according to size, replication timing and occurrence at fragile 
sites. Other configurations of structural variants and copy-number 
changes seen more than 50 times in the cohort were included as further 
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categories, including cycles, chains and bridges of templated insertions 
(also split by size), local n-jumps and local–distant clusters.
We applied two methods for signature discovery, which yielded 
comparable results. We identified 16 structural-variant signatures: 
the 12 most prevalent of these signatures are shown in Fig. 6a. Signature 
extraction on the cohort randomly split into two halves identified ten 
highly correlated signatures (Supplementary Fig. 7), which closely 
matched the signatures called in the full cohort despite the lower power. 
Three signatures of deletions emerged, split by size: the signature of 
small (<50-kb) deletions included small reciprocal inversions and the 
signature of large (>500-kb) deletions included large reciprocal inver-
sions. This implies that the frequencies of deletions and reciprocal 
inversions are correlated across the cohort, and both follow similar 
size distributions within an individual patient.
We identified five signatures of tandem duplications, split by size 
and replication timing. Cycles, bridges and chains of templated inser-
tions were particularly prominent in signatures of early-replicating 
tandem duplications, whereas local two-jump structures were more 
closely associated with late-replicating tandem duplications. All of 
these patterns exemplify the copy-and-paste concept, in which extra 
copies of genomic templates are produced and inserted as an integral 
feature of the structural-variant process.
Another signature was characterized by deletions and tandem dupli-
cations at chromosomal fragile sites35. Tandem duplications were more 
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Fig. 6 | Structural-variant signatures in human cancers. a, The 12 most 
distinctive structural-variant signatures extracted by the Bayesian hierarchical 
Dirichlet process algorithm, run on a sample size of 2,559 genomes containing 
structural variants. Here the lengths of the bars represent the estimated 
proportion of each event class assigned to each signature (rows sum to one); 
the black line segments represent the 95% posterior interval for bar length 
from the Markov chain. FB, fold-back; mid, mid-sized. b, Association of 
pathogenic mutations (germline and somatic combined) in key DNA repair 
genes with structural-variant signatures. The sample size of patients who have 
pathogenic variants in the specific genes assessed is shown in brackets after 
each gene label ( y axis). Hypothesis tests and effect sizes for each gene are 
derived from linear models for signature intensity after correction for 
histology. Significant associations from two-sided tests with correction for 
multiple hypothesis testing are shown. The colour and size of the points 
represent the estimated effect sizes. MSH refers to MSH2, MSH3, MSH4 and 
MSH6, genes in the mismatch repair pathway; FANC refers to genes associated 
with Fanconi anaemia, namely FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, 
FANCI, FANCL and FANCM.
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prominent at the edges of the fragile site, and deletions were concen-
trated in the centre (Extended Data Fig. 9a, b). The size range of fragile 
site deletions peaked at around 100 kb, similar to the larger deletion 
signature, whereas the rarer fragile-site tandem duplications showed 
no strong size peak (Extended Data Fig. 9c). Sites of fragility varied 
extensively across tumour types (Extended Data Fig. 9d).
Unbalanced translocations comprised their own signature, which 
suggests that they derive from a distinct rearrangement process in 
cancer genomes. A further signature comprised both the fold-back 
inversions that are a hallmark of breakage–fusion–bridge cycles and 
similar structures such as translocations adjacent to fold-back inver-
sions. Finally, there was a signature of balanced rearrangements, 
including reciprocal translocations and chromoplexy clusters5. This 
signature probably arises from several double-stranded DNA breaks 
(potentially occurring in interphase), in which both sides of the break 
are incorrectly repaired through ligation to other, simultaneously 
broken regions of the genome.
DNA repair genes and tumour type
We grouped annotations of pathogenic germline variants and somatic 
driver mutations in DNA-repair genes across the cohort8, correlat-
ing their presence with activity of the structural-variant signatures 
(Fig. 6b). As previously described for breast and ovarian cancers6,29, 
BRCA1 mutations are significantly associated with small tandem dupli-
cation signatures, the mechanistic basis of which is increasingly well 
understood10. As previously described6,36, CDK12 variants predicted 
signatures of mid-sized-to-large tandem duplications. BRCA2 variants 
correlated with small deletions, as expected from previous work29, 
and also with the reciprocal structural-variant signature that includes 
chromoplexy. PALB2 variants showed the same correlations with sig-
natures of small deletions and reciprocal structural variants as does 
BRCA2: PALB2 colocalizes with, stabilizes and assists BRCA2 during 
homologous recombination37, so we might have predicted that inactiva-
tion of either gene would lead to a similar structural-variant signature. 
These associations between driver mutations and structural-variant 
signatures were consistently evident across many types of tumour 
(Extended Data Fig. 10).
The structural-variant signatures showed considerable heterogene-
ity in their activity across tumour types and among patients within a 
given tumour type (Supplementary Fig. 8). Tumours of the gastroin-
testinal tract—including colorectal and oesophageal adenocarcino-
mas—showed high rates of the fragile-site signature. Prostate cancer 
was notable for the prevalence of the chromoplexy signature, as pre-
viously reported5,20, and squamous cell carcinomas of the lung were 
characterized by the fold-back inversion signature.
We assessed how classes of structural variant altered known cancer 
genes (Supplementary Table 1). Some cancer genes acquire oncogenic 
potential only with specific structural events, such as fusion genes or 
enhancer hijacking. Not surprisingly, these genes typically showed little 
variability in which classes of structural variant could generate such 
events (Extended Data Fig. 11a–c)—although there were exceptions. 
The TMPRSS2-ERG fusion gene of prostate cancer, for example, was 
generated by a range of processes (including simple deletions, chro-
moplexy and chromothripsis), all of which are prevalent signatures in 
this tumour type (Extended Data Fig. 11d–f).
Tumour-suppressor genes and recurrently amplified genes showed 
more variability in which types of structural variant were observed, 
and these were shaped by signatures active in the relevant tumour 
types. For example, the tumour-suppressor genes, PTEN and RAD51B, 
which are commonly inactivated in breast and ovarian cancers, were 
often targeted by tandem duplications generating out-of-frame exon 
duplications (Extended Data Fig. 12a, b). By contrast, deletions were 
the predominant events that inactivated SMAD4 and CDKN2A, in 
keeping with their prevalence in cancers of the gastrointestinal tract 
(Extended Data Fig. 12c, d). MYC, one of the most commonly amplified 
genes across all types of cancer, showed considerable diversity in the 
mechanisms of its rearrangement: nested tandem duplications in breast 
cancer, translocations or chromoplexy with IGH in lymphoma, as well 
as chromothripsis, cycles of templated insertions, local n-jumps and 
local–distant clusters in other types of tumour (Extended Data Fig. 13).
Discussion
We have described the patterns and signatures of structural variation in 
a large cohort of uniformly analysed cancer genomes. A major grouping 
of patterns in structural variants that emerges from our study is one in 
which extra copies of genomic templates are inserted during the rear-
rangement process. This includes simple events such as tandem dupli-
cations, as well as a range of more-complex events with duplications and 
triplications that are rearranged locally as well as inserted distantly. Our 
signature analysis grouped a large proportion of these more-complex 
events together with tandem duplications, which suggests that they 
represent a continuum of processes that share underlying properties. A 
replication-based mechanism has previously been proposed to explain 
local two-jumps4,23,24, in which stalled replication forks or other DNA 
lesions cause the DNA polymerase to switch templates and continue 
replication in a new location. Studies in experimental models are now 
revealing that a wide range of mechanisms and DNA lesions can result in 
templated insertions: these mechanisms include tandem duplications 
in BRCA1 deficiency10, translocations with templated insertions caused 
by dysregulated strand invasion38 and distant templated insertions in 
the absence of replication helicases39.
Genomic instability in cancer is not a single phenomenon. Instead, 
many different mutational processes can act to restructure the genome 
and, in doing so, generate a notably flexible array of possible structures. 
Any given tumour draws on a subset of the available processes, shaped 
by the cell of origin, germline predisposition and other, unknown, fac-
tors: selection then does the rest, promoting the clone that has chanced 
on the structure that increases its potential for self-determination.
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Methods
No statistical methods were used to predetermine sample size. The 
experiments were not randomized and investigators were not blinded 
to allocation during experiments and outcome assessment.
A detailed description of the methods used in this paper and many 
additional results are described in Supplementary Information. Here, 
we summarize the key aspects of the analysis.
Generation of the structural-variant call set
The final set of structural variants used in this Article was generated 
by the Technical Working Group of the PCAWG Consortium and is 
described in the main PCAWG paper8. In brief, four variant callers 
were used to identify somatically acquired structural variants from 
matched tumour and germline whole genome sequencing data: SvABA 
(Broad pipeline), DELLY (DKFZ pipeline), BRASS (Sanger pipeline) and 
dRanger (Broad pipeline). These were merged into a final call set using 
a graph-based algorithm to identify overlapping breakpoint junctions 
across algorithms. Detailed visual inspection of structural-variant calls 
suggested that a simple approach of accepting all structural-variant 
calls made by two or more of the four algorithms gave the best trade-off 
between sensitivity and specificity.
Structural-variant clustering and annotation
To identify clusters of structural variants, we developed a method 
for grouping structural variants into clusters and footprints to allow 
structural and mechanistic inferences to be made systematically. In 
parallel, we processed the somatic copy-number data and merged 
it with structural-variant junctions to enable us produce rearrange-
ment patterns from the generated structural-variant clusters and 
footprints. We produced normalized representations of structural-
variant cluster patterns, which enable us to tabulate the number of 
different cluster and footprint patterns and analyse their features. 
Finally, we performed manual and simulation-assisted interpretation 
of the recurrently observed cluster and footprint patterns. The indi-
vidual steps of the structural-variant classification pipeline are outlined 
below and detailed in the subsequent subsections: (1) computing the 
exact breakpoint coordinates from clipped reads; (2) removing redun-
dant ‘segment-bypassing’ structural variants; (3) merging rearrange-
ment breakpoints with copy-number data to yield structural-variant 
breakpoint-demarcated, normalized, absolute copy-number data; (4) 
clustering individual structural variants into structural-variant clusters 
and footprints; (5) heuristically refining structural-variant clusters 
and footprints; (6) filtering artefactual fold-back-type structural vari-
ants with insufficient support; (7) determining balanced overlapping 
breakpoints (this step is to distinguish very short templated insertions 
from mutually overlapping balanced breakpoints); and (8) computing 
rearrangement patterns and categories.
Distribution of structural variants across the genome
We divided the hg19 human reference genome (autosomes and chromo-
some X) into 3,036,315 pixels of 1 kb, and calculated a suite of metrics 
per pixel to summarize a variety of genome properties with potential 
relevance to the distribution of rearrangements, as listed in the Sup-
plementary Information. Properties were matched as closely as possible 
to the tissue of origin for cancer samples from the PCAWG data. All 
other genome properties were held fixed across all tissues. To test for 
associations between structural-variant event classes and the library 
of genome properties, the genome property metrics were compared 
between real structural-variant positions (randomly choosing one side 
of each breakpoint junction to reduce dependence between observa-
tions) and one million uniform random positions from the callable 
genome space. To compare the tissue-specific properties, each ran-
dom position was assigned a random tissue type, drawing from the 
observed tissue-type distribution in the structural-variant call set. 
For each genome property and each event class, the real observations 
were pooled amongst the random ones, and then rank-transformed 
and normalized on a scale from 0 to 1. Under the null hypothesis of no 
event-versus-property association, the ranks of the real observations 
would follow a uniform distribution. We tested this in each case with 
a Kolmogorov–Smirnov test then applied a Benjamini–Yekutieli cor-
rection for false-discovery rate across the entire suite of tests and set 
the threshold for significance reporting at 0.01.
Structural-variant-signature analysis
We used two algorithms for extracting structural-variant signatures. 
Both used the same input files, comprising a matrix of counts per 
patient (across all patients) of structural-variant clusters falling into 
a number of mutually exclusive categories. These categories included 
the major classes of structural variants, with the more-common events 
(deletions, tandem duplications and inversions) split by size and/or 
replication timing. The two algorithms that were  used for extracting 
the signatures were (1) a hierarchical Dirichlet process and (2) non-
negative matrix factorization. Further details on the implementation 
of these algorithms are available in the Supplementary Information.
Reporting summary
Further information on research design is available in the Nature 
Research Reporting Summary linked to this paper.
Data availability
Somatic and germline variant calls, mutational signatures, subclonal 
reconstructions, transcript abundance, splice calls and other core data 
generated by the ICGC/TCGA PCAWG Consortium are described in an 
accompanying Article8 and are available for download at https://dcc.
icgc.org/releases/PCAWG. Additional information on accessing the 
data, including raw read files, can be found at https://docs.icgc.org/
pcawg/data/. In accordance with the data access policies of the ICGC 
and TCGA projects, most molecular, clinical and specimen data are in an 
open tier that does not require access approval. To access information 
that could potentially identify participants, such as germline alleles 
and the underlying sequencing data, researchers will need to apply to 
the TCGA data access committee via dbGaP (https://dbgap.ncbi.nlm.
nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the 
dataset, and to the ICGC data access compliance office (http://icgc.org/
daco) for the ICGC portion of the dataset. In addition, to access somatic 
single-nucleotide variants derived from TCGA donors, researchers will 
also need to obtain dbGaP authorization.
Code availability
The core computational pipelines used by the PCAWG Consortium 
for alignment, quality control and variant calling are available to the 
public at https://dockstore.org/search?search=pcawg under the GNU 
General Public License v.3.0, which allows for reuse and distribution. 
These are described in detail in an accompanying Article8. The code 
for grouping structural variants into structural-variant clusters and 
footprints is available at https://github.com/cancerit/ClusterSV/ (ver-
sion 1.0). The code for simulating rearrangements can be found at 
https://github.com/cancerit/SimSvGenomes (version 1.0). The code 
for sampling from the hierarchical Dirichlet process for identification 
of mutational signatures is implemented as an R package at https://
github.com/nicolaroberts/hdp (version 0.1.1). 
Acknowledgements This work was supported by the Wellcome Trust, Pediatric Low-Grade 
Astrocytoma Fund and the Fund for Innovation in Cancer Informatics. P.J.C. is a Wellcome Trust 
Senior Clinical Fellow (WT088340MA). We acknowledge the contributions of the many clinical 
networks across ICGC and TCGA, which provided samples and data to the PCAWG 
Consortium, and the contributions of the Technical Working Group and the Germline Working 
Group of the PCAWG Consortium for the collation, realignment and harmonized variant-
calling of the cancer genomes used in this study. We thank the patients and their families for 
their participation in the individual ICGC and TCGA projects.
Author contributions Y.L., N.D.R., J.A.W. and O.S. contributed equally to this manuscript, 
undertaking evaluation and curation of structural-variant calls, merging structural-variant call 
sets from four separate algorithms into a final dataset. Y.L. performed the clustering and 
classification of structural variants, and identified patterns of rearrangement, with assistance 
from N.D.R. and M.I. N.D.R. performed the analysis of structural-variant signatures with 
assistance from Y.L. N.D.R., J.A.W. and O.S. analysed the distribution of structural variants 
across the genome, with input from J.E.H., E.K., K.K. and S.E.S. S.W. and J.O.K. contributed to 
the analysis of how germline variants influenced signatures of structural variants. J.W., R.B. and 
P.J.C. jointly oversaw the project, assisted with data interpretation and wrote the paper, with 
input from all authors.
Competing interests R.B. owns equity in Ampressa Therapeutics; M.M. is the scientific 
advisory board chair of—and consultant for— OrigiMed, and receives research funding from 
Bayer and Ono Pharma, and patent royalties from LabCorp.; J.W. is a consultant for Nference 
Inc.; C.-Z.Z. is a cofounder and equity holder of Pillar Biosciences, a for-profit company 
specializing in the development of targeted sequencing assays.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41586-019-
1913-9.
Correspondence and requests for materials should be addressed to J.W., R.B. or P.J.C.
Peer review information Nature thanks Don Conrad, Ben Lehner and the other, anonymous, 
reviewer(s) for their contribution to the peer review of this work.
Reprints and permissions information is available at http://www.nature.com/reprints.
Article
800
0
100
200
Skin−Melanoma
(100 most rearranged)
400
200
0
200
400
600
Prost−AdenoCA
(100 most rearranged)
200
0
100
200
300
Panc−AdenoCA
(100 most rearranged)
200
0
200
400
600
Ovary−AdenoCA
(100 most rearranged)
0
500
1000
Lymph−BNHL
(100 most rearranged)
400
200
0
200
400
600
Liver−HCC
(100 most rearranged)
1050
0
50
100
Kidney−RCC
(100 most rearranged)
140
0
20
40
60
CNS−Medullo
(100 most rearranged)
500
0
500
1000
Breast−AdenoCA
(100 most rearranged)
70
35
0
5
10
15
Lymph−CLL
6
0
2
4
CNS−PiloAstro
200
0
200
400
Eso−AdenoCA
200
0
50
100
Panc−Endocrine
1000
0
500
1000
Stomach−AdenoCA
100
0
50
100
150
Head−SCC
200
0
200
400
ColoRect−AdenoCA
20
0
5
10
Thy−AdenoCA
500
0
500
Lung−SCC
200
0
20
40
Kidney−ChRCC
200
0
100
200
300 Uterus−AdenoCA
220
0
20
40
60
CNS−GBM
300
0
100
200
Lung−AdenoCA
600
0
100
200
Bone−Osteosarc
200
0
50
100
Biliary−AdenoCA
300
0
100
200
Bladder−TCC
1300
0
100
200
300
SoftTissue−Liposarc
40
0
10
20
CNS−Oligo
50
0
50
100
Cervix−SCC
250
0
50
100
SoftTissue−Leiomyo
SV event class
Complex, uncl
Del
Tandem Dup
Recip Trans
Unbal Trans
Recip Inv
Unbal Inv
Foldback
Loc 2−Jump
Templ Ins
Cplxy
Trans Plus
Extended Data Fig. 1 | Per-sample counts of structural-variant breakpoint 
junctions by histology group. Counts of simple, classified structural variants 
are shown above the x axis and counts of complex breakpoint junctions below 
the x axis. Patients within each tumour type are ranked by frequency of simple 
structural variants.
A
B
C
C
op
y 
N
um
be
r
chr1
chr17
chr21



10kb
0
2
4
6
8
0
2
4
0
2
4
6
C
op
y 
N
um
be
r
chr5
chr12


10kb
0
2
4
0
2
4
C
op
y 
N
um
be
r
chr1
chr3


1kb
0
2
4
6
8
0
2
4
6
C
op
y 
N
um
be
r
chr2
chr4


100bp
0
2
4
0
2
4
C
op
y 
N
um
be
r
chr8
chr22
chr16



100bp
0
2
4
6
0
2
4
0
2
4
C
op
y 
N
um
be
r
chr14
chr2


100kb
0
2
4
0
2
4
Uterus-AdenoCA
Ovary-AdenoCA
Ovary-AdenoCA
Ovary-AdenoCABreast-AdenoCA
ColoRect-AdenoCA
OR
OR
OR
Cycle of templated insertions
Bridge of templated insertions
Chain of templated insertions
Extended Data Fig. 2 | Further examples of templated insertion chains, cycles and bridges. Schematics follow the same structure as in Fig. 3.
Article
0
500
1000
2 3 4+
Number of breakpoint junctions
E
ve
nt
 c
ou
nt
Ins Chain
Ins Bridge
Ins Cycle
Templated Insertions
C
op
y 
N
um
be
r
Panc−AdenoCA SA411786 Ins Cycle
chr1
chr12
chr21
chr6
chr11
●
●
●
●
●
10kb
0
2
4
6
8
0
2
4
6
0
2
4
0
2
4
6
0
2
4
6
C
op
y 
N
um
be
r
Uterus−AdenoCA SA514439 Ins Cycle
chr2
chr4
chr8
chr14
chr3
chr22
chr21







100kb
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
0
2
4
6
One possible derivative chromosome
(of 7, depending on where cycle starts)
One possible derivative chromosome
(of 6, depending on where cycle starts)
A B
C
Cycle of templated insertions
Cycle of templated insertions
Extended Data Fig. 3 | Number of breakpoint junctions in cycles, bridges and 
chains of templated insertions. a, Histogram of numbers of breakpoint 
junctions in templated insertion cycles, chains and bridges across all samples 
in all tumour types in the cohort. b, c, Two examples of particularly long cycles 
of templated insertions in the cohort. Examples are depicted in a similar 
manner to those in Fig. 3.
30
16
9
41
Liver−HCC
Skin−Melanoma
SoftTissue−Liposarc
Other 10kb
TERT CLPTM1LSLC6A19 SLC6A18
0
10
100
1000
10000
1,200,000 1,300,000
chr5
D
is
ta
nc
e 
to
 n
ex
t b
re
ak
po
in
t
Complex, unclassified
Deletion
Tandem Duplication
Reciprocal Translocation
Unbalanced Translocation
Reciprocal Inversion
Unbalanced Inversion
Foldback inversion
Local 2−Jump
Templated Insertions
Chromoplexy
Translocation Plus (local-distant)
C
op
y 
N
um
be
r
Liver−HCC SA529759 Ins Cycle
chr4:155257160−155577853
chr5:947917−1345520


100kb
0
2
4
0
2
4
DCHS2 PLRG1
FGB
FGA FGG
LRAT 
NKD2 SLC12A7
SLC6A19
SLC6A18
CLPTM1L
TERT 
C
op
y 
N
um
be
r
Liver−HCC SA529777 Ins Cycle
chr5:977538−1345132
chr8:126337800−126694023


100kb
0
2
4
0
2
4
NKD2 SLC12A7
SLC6A19
SLC6A18
CLPTM1L
NSMCE2 TRIB1
TERT 
C
op
y 
N
um
be
r
Liver−HCC SA540506 Ins Chain
chr5:931784−1354359
chr1:8174260−8530197
chr20:48404012−48504011



100kb
0
4
8
0
4
8
12
0
4
8
12
SLC45A1 RERE
NKD2 SLC12A7
SLC6A19
SLC6A18
CLPTM1L
SLC9A8
TERT 
OR ** *
OR *
* *
*
A
B
C
D
Cycle of templated insertions
Chain of templated insertions
Cycle of templated insertions
E TERT expression in Liver-HCC
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
0.1
10.0
None SNV Templ Ins SV near TSS
TERT alteration status
T
E
R
T
 e
xp
re
ss
io
n,
 lo
gR
P
K
M
Extended Data Fig. 4 | Templated insertion events that activate TERT in 
hepatocellular carcinoma. a, The positions of all structural-variant 
breakpoints in the TERT region in the PCAWG cohort (including 50-kb flanks 
either side of TERT), coloured by classification and vertically spaced by the 
distance to the next breakpoint in the cohort. If the two sides of a breakpoint 
junction are contained within the plotting window, they are joined by a curved 
line. The number of samples with a breakpoint in the plotting window is 
annotated in the table in the top left. b–d, Examples of two cycles and a chain of 
templated insertions that affect TERT in hepatocellular carcinomas. e, 
Expression levels of TERT in patients with hepatocellular carcinoma 
(n = 187 patients), separated by whether TERT was wild type, had an activating 
promoter point mutation, structural variants in a templated insertion or other 
class. Individual patient data are shown as points. The box shows the median 
expression level as a thick black line, with the range of the box denoting the 
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Extended Data Fig. 6 | Size distribution of tandem duplications. a, Size 
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Extended Data Fig. 8 | Relationship of an extended panel of genomic 
properties with structural-variant categories. Associations between a subset 
of the genomic properties (rows) and classes of structural variant (columns). 
Each density curve represents the quantile distribution of the genomic 
property values at observed breakpoints, compared to random genome 
positions. Asterisks indicate significant departures from uniform quantiles 
after multiple hypothesis correction by the Benjamini–Yekutieli method on a 
one-sided Kolmogorov–Smirnov test, based on a sample size of 2,559 genomes 
containing structural variants: *false-discovery rate < 0.01, **false-discovery 
rate < 0.001, ***false-discovery rate < 10−6. Cells with significant property 
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quantile above (blue) or below (red) 0.5. The interpretation of each property 
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Extended Data Fig. 9 | Properties of structural variants at chromosomal 
fragile sites. a, Structural-variant breakpoints in the most affected fragile 
sites: FHIT, MACROD2 and WWOX. These are coloured by classification and 
vertically spaced by the distance to the next breakpoint in the cohort. If the two 
sides of a breakpoint junction are contained within the plotting window, they 
are joined by a curved line. The number of samples with a breakpoint in the 
plotting window is annotated in the tables at the top left. b, Number of 
deletions and tandem duplications (top) and number of affected samples 
(bottom) for the 18 fragile sites considered in this analysis. c, Size distribution 
of deletions and tandem duplications in fragile sites (FS) compared to the rest 
of the genome. d, Fragile-site preference for 20 cancer histology groups as 
indicated by the proportion of samples that contains a deletion in each of the 
18 fragile sites considered here. The number of samples is indicated in 
parentheses.
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Extended Data Fig. 10 | Consistency of associations between signatures and 
mutations in DNA-repair genes. a, Box-and-whisker plots showing the number 
of structural variants attributed to the small-deletion signature in different 
types of tumour, split by BRCA2 status (BRCA2 wild type in orange; 
BRCA2 mutant in cyan). The box denotes the interquartile range, with the 
median marked as a horizontal line. The whiskers extend as far as the range or 
1.5× the interquartile range, whichever is lower. Outlier patients are shown as 
points. There is an increase in events attributed to the small-deletion signature 
when BRCA2 is mutated, across multiple types of tumour (breast, pancreatic, 
ovarian, prostate, lung squamous and so on). b, Box-and-whisker plots as for a, 
showing the number of structural variants attributed to the small-deletion 
signature in different types of tumour, split by PALB2 status. c, Box-and-whisker 
plots as for a, showing the number of structural variants attributed to the early-
replicating, small-tandem-duplication signature in different types of tumour, 
split by BRCA1 status. d, Box-and-whisker plots as for a, showing the number of 
structural variants attributed to the large-tandem-duplication signature in 
different types of tumour, split by CDK12 status.
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Extended Data Fig. 11 | See next page for caption.
Extended Data Fig. 11 | Patterns of structural variants causing fusion genes 
and enhancer hijacking. a, Rainfall plot of structural-variant breakpoints in 
the genes KIAA1549 and BRAF, commonly fused together through a tandem 
duplication in pilocytic astrocytomas. Structural variants are coloured by 
classification and arranged vertically by the distance to the next breakpoint in 
the cohort. If the two sides of a breakpoint junction are contained within the 
plotting window, they are joined by a curved line. The number of samples with a 
breakpoint in the plotting window is annotated in the table at the top of each 
panel. b, Rainfall plot of structural-variant breakpoints that affect RET, 
commonly fused to CCDC6 by inversion in papillary thyroid cancer. c, Rainfall 
plot of structural-variant breakpoints that affect BCL2, commonly hijacked to 
the IGH immunoglobulin locus by translocations in B cell lymphomas. d, 
Rainfall plot of structural-variant breakpoints that affect ERG, commonly fused 
with TMPRSS2 by deletion or more-complex events in prostate 
adenocarcinoma. e, Example of a TMPRSS2-ERG fusion gene in a prostate 
adenocarcinoma created by a chromoplexy cycle. The estimated copy-number 
profile is shown as black horizontal segments, with structural variants shown 
as dotted arcs linking the edges of two copy-number segments. f, Example of a 
TMPRSS2-ERG fusion gene in a prostate adenocarcinoma created by 
chromothripsis.
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Extended Data Fig. 12 | Patterns of structural variants that affect selected 
tumour-suppressor genes. a, Rainfall plot of structural-variant breakpoints in 
the gene PTEN, commonly inactivated in breast and ovarian adenocarcinomas, 
in which tandem-duplication signatures are frequent. Structural variants are 
coloured by classification and arranged vertically by the distance to the next 
breakpoint in the cohort. If the two sides of a breakpoint junction are contained 
within the plotting window, they are joined by a curved line. The number of 
samples with a breakpoint in the plotting window is annotated in the table at 
the top of each panel. b, Rainfall plot of structural-variant breakpoints that 
affect RAD51B, commonly inactivated in breast and ovarian adenocarcinomas. 
c, Rainfall plot of structural-variant breakpoints that affect CDKN2A, 
commonly inactivated in tumours of the gastrointestinal tract, in which 
deletion signatures are common. d, Rainfall plot of structural-variant 
breakpoints that affect SMAD4, commonly inactivated in tumours of the 
gastrointestinal tract.
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Extended Data Fig. 13 | Examples of structural variants increasing the copy number of MYC. The estimated copy-number profile is shown as black horizontal 
segments, with structural variants shown as dotted arcs linking the edges of two copy-number segments.
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Extended Data Table 1 | Glossary of key terms
Term Description 
Structural variant (SV) Juxtaposition of non-contiguous chromosomal segments through a process of genomic 
rearrangement. 
Breakpoint The chromosomal position at which a DNA break is made. Each SV consists of a junction 
between two breakpoints in different regions of the genome. 
Copy number 
alteration (CNA) 
Change in the number of copies of a given chromosomal segment from that expected.  
Reciprocal or balanced 
SV 
A pair of SVs in which both sides of a single dsDNA break are rescued in the 
rearrangement. Typically used to describe some inversions and some translocations. 
Unbalanced SV An SV (usually inversion or translocation) in which only one side of the dsDNA break is 
rescued, thereby generating a copy number alteration across the breakpoint.  
Cluster of SVs A set of SVs that are closer together in genomic space than expected by chance. Typically, 
such clustering implies a shared mechanistic basis for the SV generation.  
Derivative 
chromosome 
A chromosome that carries one or more SVs. 
Phased SVs Set of SVs and copy number alterations in a cluster carried on a single derivative 
chromosome. 
Chromosomal 
segment 
A contiguous stretch of DNA that is of constant copy number, used to denote the regions 
of chromosome between SVs. 
Template A region of chromosomal DNA that is copied and inserted elsewhere in the genome. 
SV class A type of structural variant, such as deletion, tandem duplication or translocation. 
Deletion Loss of a segment of chromosome from the genome spanned by a junction between the 
two breakpoints either side. 
Tandem duplication Extra copy of a segment of chromosome in which the duplicated region is inserted 
immediately adjacent to the original template in the same orientation.  
Reciprocal inversion A segment of chromosomal DNA inserted into its original position, but in the opposite 
orientation. 
Fold-back inversion An inverted rearrangement between two breakpoints typically <20kb apart on the 
chromosome, with associated copy number change. Often a sign of breakage-fusion-
bridge cycles. 
Translocation Breakpoint junction between two different chromosomes, either reciprocal or unbalanced. 
Breakage-fusion-
bridge cycle 
SV mechanism in which a naked DNA end (breakage) is copied to its sister chromatid 
during S phase, with the two ends undergoing fusion (by fold-back inversion). At 
anaphase, the resulting dicentric chromosome is stretched between the two daughter cells 
(bridge), leading to further DNA breakage and potentially further cycles. 
Chromoplexy A set of >2 reciprocal SVs in which the chromosomal ends either side of each breakpoint 
are shuffled such that every end is rescued in a rearrangement junction. 
Chromothripsis A cluster of many SVs (10s to 100s) in one or a few chromosomes, occurring in a single 
catastrophic event, with oscillating copy number profile and rearrangement junctions of all 
four possible orientations.  
Local n-jump A cluster of n SVs in a single genomic region, typically phased to a single derivative 
chromosome, exhibiting some copy number gains and junctions with inverted and non-
inverted orientation. 
Cycle, chain or bridge 
of templated insertions 
Copies of one or more genomic templates drawn from across the genome, strung together 
in a contiguous string and inserted into a single derivative chromosome. A chain of 
templated insertions does not return to the original chromosome, leading to an unbalanced 
translocation. A cycle has a duplication on the host chromosome, while a bridge inserts 
the template copies into a deletion on the host chromosome. 
Local-distant cluster A cluster of SVs that has both local rearrangements and rearrangements to other parts of 
the genome. 
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection Workflow Step Algorithm Version Dockstore Package* 
WGS Alignment BWA-MEM v0.7.8-r455 https://goo.gl/oqp4Xd 
EMBL/DKFZ SV caller  DELLY v0.6.6 https://goo.gl/Y46MCo 
EMBL/DKFZ SCNA caller ACEseq v1.0.189 https://goo.gl/4zoV42 
EMBL/DKFZ SNV caller DKFZ somatic SNV workflow 1.0.132-1  
EMBL/DKFZ indel caller Platypus v0.7.4  
Sanger SCNA caller ascatNgs  v1.5.2 https://goo.gl/9DSrbA 
Sanger SV caller BRASS v4.012  
 grass v1.1.6  
Sanger SNV caller CaVEMan  v1.50  
Sanger indel caller Pindel  v1.5.7  
Broad SCNA caller ABSOLUTE/JaBbA v1.5/? https://goo.gl/YkdtDt 
Broad SV caller SvABA/dRanger/BreakPointer 2015-05-20/2016-03-13/2015-12-22  
Broad SNV caller MuTect v1.1.4  
Broad indel caller SvABA 2015-05-20  
MuSE SNV caller MuSE v1.0rc https://goo.gl/5SR4bF 
SMuFIN indel caller SMuFIN 2014-10-26 https://goo.gl/EuUP5k 
Oxidative artefact filter OxoG 2016-4- 28   https://goo.gl/cUKP9K 
SNV/Indel annotation VAGrENT v2.1.2 https://goo.gl/9DSrbA 
 ANNOVAR  v2014Nov12 https://goo.gl/4zoV42 
miniBAM generation VariantBAM v2017Dec12 https://goo.gl/S8h8e5 
SNV/Indel merging and consensus generation SNV-MERGE v2017May26 https://goo.gl/TETSB8 
SV merging and consensus generation SV-MERGE v2017Dec12 https://goo.gl/A9CEup 
Strand bias filter DKFZ Strand Bias Filter v2016Dec15 https://goo.gl/8jXrvZ 
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Data analysis We have described the algorithms in detail throughout the manuscript. Signatures analysis used the published NMF algorithm (PMID: 
23318258) and an unpublished Bayesian method, released on github (https://github.com/nicolaroberts/hdp).
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The PCAWG-generated alignments, variant calls, annotations and derived data sets are available for general research use for browsing and download at http://
dcc.icgc.org/pcawg/. In accordance with the data access policies of the ICGC and TCGA projects, most molecular, clinical and specimen data are in an open tier 
which does not require access approval. To access potentially identifying information, such as germline alleles and underlying read data, researchers will need to 
apply to the TCGA Data Access Committee (DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the data set, 
and to the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) for the ICGC portion. 
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For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size We compiled an inventory of matched tumour/normal whole cancer genomes in the ICGC Data Coordinating Centre. Most samples came 
from treatment-naïve, primary cancers, but there were a small number of donors with multiple samples of primary, metastatic and/or 
recurrent tumours. Our inclusion criteria were: (i) matched tumour and normal specimen pair; (ii) a minimal set of clinical fields; and (iii) 
characterisation of tumour and normal whole genomes using Illumina HiSeq paired-end sequencing reads.  
We collected genome data from 2,834 donors, representing all ICGC and TCGA donors that met these criteria at the time of the final data 
freeze in autumn 2014.  
 
No formal power calculations were performed to decide sample size for PCAWG - we aggregated all genomes available at the time. 
Data exclusions After quality assurance, data from 176 donors were excluded as unusable. Reasons for data exclusions included inadequate coverage, 
extreme bias in coverage across the genome, evidence for contamination in samples and excessive sequencing errors (for example, through 8-
oxoguanine). Data exclusion criteria were pre-established.
Replication In order to evaluate the performance of each of the mutation-calling pipelines and determine an integration strategy, we performed a large-
scale deep sequencing validation experiment. We selected a pilot set of 63 representative tumour/normal pairs, on which we ran the three 
core pipelines, together with a set of 10 additional somatic variant-calling pipelines contributed by members of the SNV Calling Working 
Group. To assess accuracy of SV calls, we therefore used the property that an SV must either generate a copy number change or be balanced, 
whereas artefactual calls will not respect this property. For individual SV callers, we estimated the true positive rate to be in the range 80-95% 
for samples in the pilot-63 dataset.
Randomization Not applicable - this was a descriptive study.
Blinding Not applicable - this was a descriptive study.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
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Materials & experimental systems
n/a Involved in the study
Antibodies
Eukaryotic cell lines
Palaeontology
Animals and other organisms
Human research participants
Clinical data
Methods
n/a Involved in the study
ChIP-seq
Flow cytometry
MRI-based neuroimaging
Human research participants
Policy information about studies involving human research participants
Population characteristics Patient-by-patient clinical data are provided in the marker paper for the PCAWG consortium (Extended Data Table 1 of that 
manuscript). Demographically, the cohort included 1,469 males (55%) and 1,189 females (45%), with a mean age of 56 years 
(range, 1-90 years). Using population ancestry-differentiated single nucleotide polymorphisms (SNPs), the ancestry distribution 
was heavily weighted towards donors of European descent (77% of total) followed by East Asians (16%), as expected for large 
contributions from European, North American and Australian projects. We consolidated histopathology descriptions of the 
tumour samples, using the ICD-0-3 tumour site controlled vocabulary. Overall, the PCAWG data set comprises 38 distinct tumour 
types. While the most common tumour types are included in the dataset, their distribution does not match the relative 
population incidences, largely due to differences among contributing ICGC/TCGA groups in numbers sequenced. 
Recruitment Patients were recruited by the participating centres following local protocols. Samples obtained had to meet criteria on amount 
of tumour DNA available, meaning that the cohort is potentially somewhat biased towards larger tumours. Otherwise, we 
anticipate no major recruitment biases.  
Ethics oversight The Ethics oversight for the PCAWG protocol was undertaken by the TCGA Program Office and the Ethics and Governance 
Committee of the ICGC. 
Note that full information on the approval of the study protocol must also be provided in the manuscript.
